News

As the coronavirus spreads, deaths mount and fears grow across the globe, biotech companies, universities and government agencies scramble – some together, others alone – for a vaccine to contain it.

When a Duke-led research team won a $300 million federal grant to help develop an AIDS vaccine in 2005, the global situation was looking grim.

An international commission of global experts convened by the International AIDS Society and The Lancet in 2018 advised that to eliminate HIV, global treatment efforts should be complemented by a robust scale-up in primary HIV prevention, including the development of a preventive vaccine.

The CDC’s Immunization Safety Office, Duke Human Vaccine Institute and Kaiser Permanente Vaccine Study Center conducted a clinical study, funded by the CDC’s Clinical Immunization Safety Assessment (CISA) Project, to assess whether the risk of fever, and potentially febrile seizure, might be reduced by administering the quadrivalent inactivated influenza vaccine (IIV4) separately from the pneumococcal (PCV13) and diphtheria-tetanus-pertussis (DTaP) vaccines.

Take a moment to watch the Duke Health Live Video Series.

Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.

The DHVI was pleased to have Theaya Willis and Nicholas Antonicci from the Duke Center for Sexual and Gender Diversity (CGSD) join us for an informative presentation on how to create a diverse and inclusive work environment.

A clinical trial in which healthy adults will be deliberately infected with influenza virus under carefully controlled conditions is recruiting volunteers at four Vaccine and Treatment Evaluation Units (VTEUs) supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

A hydrogen peroxide-based vaccine technology that’s already being tested to fight West Nile Virus will now also be studied to combat the tropical disease yellow fever.

As part of a massive national effort to improve and modernize flu shots, the Duke Human Vaccine Institute has received three research contracts from the National Institute of Allergy and Infectious Diseases (NIAID), with an initial award of approximately $29.6 million in first-year funding.